摘要
为观察良、恶性乳腺疾病卵巢激素含量的变化，及其与免疫细胞化学测定结果之间可能存在的关系。对经病理确诊的107例病例（其中浸润性乳腺导管癌31例，纤维腺瘤49例及小叶增生27例）严格区对，检测了各组激素含量与免疫细胞化学抗体（抗细胞增殖抗原Ki67、抗肿瘤抑制基因P53蛋白产物、抗原癌基因C－erbB－2蛋白产物，抗雌激素受体、抗孕激素受体），并对测定结果进行对照。结果表明：浸润性导管癌和纤维腺瘤之间，总雌二醇（TE2）、游离雌二醇（FE2）含量均有极显著差异（P＜0．01），Pg也有显著性差异（P＜0．05）。浸润性导管癌与小叶增生之间，TE2有显著性差异（P＜0．05），FE2与Pg无明显差异（P＞0．05），而纤维脉瘤和小叶增生之间，TE2、FE2和Pg均无明显差异（P＞0．05）。提示雌激素含量可判别乳腺癌高危妇女，对这些妇女定期普查或用抗雌激素治疗可能可以预防乳腺癌的发生。对乳腺组织进行了细胞增殖抗原Ki67、肿瘤抑制基因P53、原癌基因C－erbB－2和激素受体ER、PR的检测，并与TE2、FE2和孕酮（Pg）进行比较。结果表明：浸润性导管癌P53与FE2含量差异有显著性，与TE2和Pg无明显差异（P＞0．05）。浸润性导管癌TE2、FE2和Pg与Ki67和C－erbB－2阳性与否差异无显著性。浸润性导管癌TE2、FE2和Pg?
The serum hormone Ievels of total estradiol (TE2 ), free estradiol (FE2 )and progeterone (Pg) were mea-sured by radioimmunoassay on 107 carefully designed cases, including 31 intraductal breast carcinoma, 49 fibroadenomasand 27 cystic hyperplasia, which all confirmed by pathology. And also we compared the hormone levels with the resultsof immunocytochemistry (ki-67,P53,c-erbB-2,ER and PR ) on each group. The results showed that between intraductalcarcinoma and fibroadenomas, the TE2 and FE2 was significantly different(P<0. 01 ) and Pg was different(P<0. 05).Between intraductal breast carcinom and cystic hyperplasia, there was difference in TE2(P<0. 05), but no difference inFE2 and Pg(P>0. 05). There was no difference in the hormone levels between fibroadenomas and cystic hyperplasia(P>0. 05). The relati0n between the results of immunocytochemistry and hormone levels showed that FE2 was higher inP53 protein product positive cases than in P53 negtive cases of intraductal breast carcinoma (P<0. 05). The levels ofTE2 and Pg were Iower in ER positive cases than in ER negtive cases of intraductal breast carcinoma(P<0.05). Theother results of immunocytochemistry were fail to correlated significantly with the levels of hormones.
出处
《上海医学》
CAS
CSCD
北大核心
1997年第2期76-78,共3页
Shanghai Medical Journal
基金
上海市科委自然科学基金!94ZB14021
